Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dance Biopharm rebrands to Aerami Therapeutics

September 25, 2019 By Danielle Kirsh

aerami-therapeutics

Dance Biopharm today said it rebranded as Aerami Therapeutics and will move its headquarters to Durham, N.C. The rebranding comes as the company seeks strategic partners for its Dance 501 inhaled human insulin. The company also hopes the rebranding will help progress into pivotal registration studies and expand to include inhaled therapeutics for endocrinology diseases. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured Tagged With: Aerami Therapeutics, dancebiopharm

Dance Biopharm raises $21m for insulin delivery device

June 11, 2019 By Sarah Faulkner

Dance Biopharm

Dance Biopharm has raised $21 million from 283 investors as part of a $59.2 million offering, according to a document filed with the SEC this week. The privately-held California-based company’sĀ Dance 501 device stores a liquid formulation of recombinant human insulin in a hand-held electronic inhaler. Using a vibrating mesh, the device produces particles of liquid […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals Tagged With: dancebiopharm

Dance Biopharm Holdings raises $20.5M in private investment financing round

May 3, 2019 By Danielle Kirsh

Dance Biopharm

Privately-heldĀ Dance Biopharm said yesterday that it has completed a private equity financing round to secure about $20.5 million in gross proceeds. The financing round was insider-only with a number of institutional and individual accredited investors participating. Molex Ventures made a substantial equity investment in Dance Biopharm, according to the company. Molex has been involved in […]

Filed Under: Diabetes, Funding Roundup Tagged With: dancebiopharm

Dance Biopharm raises $24m for inhaled insulin device

September 25, 2018 By Sarah Faulkner

Dance Biopharm

Privately-held Dance Biopharm said yesterday that it raised $24.5 million in a private equity round to help fund the development of its inhaled insulin product. SternAegis Ventures was the exclusive placement agent for the offering. Molex Ventures, an electronics company working with Dance to develop a connected insulin delivery device, contributed to the round. The […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: dancebiopharm

Dance Biopharm, Phillips-Medisize ink deal for inhaled insulin device

December 4, 2017 By Sarah Faulkner

Phillips-Medisize

Privately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin. The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: dancebiopharm, philips-medisize

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS